Breaking News, Collaborations & Alliances

Alnylam, Takeda in RNAi Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alnylam Pharmaceuticals and Takeda Pharmaceutical Co. Ltd. have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas. This collaboration provides Takeda with broad, worldwide, non-exclusive access to and enablement with Alnylam’s RNAi therapeutics platform technology and intellectual property in the fields of oncology and metabolic disease, with the right to expand the number of the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters